Validation of a tissue-based predictive RNA test for immunotherapy benefit in NSCLC: the PREDAPT study

npj Precision Oncology 2026 Open access

Read full text
Authors: Kevin C. Flanagan, Jon Earls, Jeffrey Hiken, Rachel L. Wellinghoff, Michelle M. Ponder, Kyle Pemberton, O. Kenneth Macdonald, Karim Youssry Welaya, Andrew William Pippas, Karl J. D’Silva, Xingwei Sui, Warren L. Alexander
+14 more Jennifer Nadine Slim, Steven J. Saccaro, Todd D. Shenkenberg, Samuel D. Bailey, Scott A. Sonnier, Georges Azzi, Bruce B. Bank, Steven E. Kossman, Paul Alan Gonzales, James Lloyd Wade, Jessica A. Hellyer, Howard L. McLeod, Eric J. Duncavage, Jarret I Glasscock
DOI: 10.1038/s41698-026-01632-6
Cited by: 0
References: 23

Abstract

ABSTRACT Lung cancer remains the leading cause of cancer mortality worldwide. Immune checkpoint inhibitors targeting PD-1/PD-L1 have significantly improved outcomes in a subset of patients. OncoPrism, a clinical test employing a multidimensional predictive RNA-based immune biomarker, was evaluated for predicting immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) patients. This study included data from 1,487 patients and evaluated OncoPrism across four NSCLC cohorts: one PD-L1 inhibitor cohort (n=195), one PD-1 inhibitor cohort (n=89), and two non-ICI cohorts (n=193 and n=1,010, respectively). In the PD-L1 inhibitor cohort, OncoPrism predicted progression-free survival (p

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis Radiomics and Machine Learning in Medical Imaging

Publication details

Journal / source
npj Precision Oncology
Publisher
Springer Science and Business Media LLC
Volume
10
Issue
1
Publication date
29 July 2026
Language
EN